Navigation Links
Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
Date:12/1/2008

e at least 3 times a day for 36 days, testing on each site-finger, palm and forearm-with each of the 3 competitor brands and 1 of the ACCU-CHEK products. After testing was completed, responses by subjects to the products were compared. In a second experiment in a laboratory setting, the ACCU-CHEK Multiclix and ACCU-CHEK Softclix Plus lancing devices were compared individually to competitor lancing devices.

"There is no question that better management of diabetes results in better outcomes for the patient," Aspy said. "By offering a lancing device that results in least painful testing, we are helping to remove one of the barriers to adequate testing for improved diabetes management."

The comparative pain study was conducted by Dr. Richard Koubek, of Koubek and Associates, on behalf of Roche.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management-from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's largest biotech company and an innov
'/>"/>

SOURCE Roche Diabetes Care
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
4. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Seniors Can Be Heartened by New Study on Statins
8. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
9. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... to release its second quarter 2011 financial results on Tuesday, ... financial markets.  The Company will also host a conference call ... 2011 to discuss its financial results and provide an update ...
... CHADDS FORD, Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... phase 2 study comparing the novel investigational drug axomadol against ... chronic low back pain. The results indicate that axomadol did ... completing additional analyses of the data and evaluating the path ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... who eat fish or seafood at least once a week have ... studied a group of 1205 people aged over 65 //and without ... consuming meat, fish and seafood, then followed them up to, five ... seafood at least once a week had a significantly lower risk ...
... the latest study done by the researchers of University of ... the cause if you have abdominal pain, gas and diarrhea.// ... and diarrhea and no obvious reason can be found. They ... with these symptoms may be unable to digest fructose. ...
... study it is indicative that systolic blood pressure is ... with impaired consciousness. This means doctors may now have ... using expensive and time-consuming imaging technology. ,Researchers studied ... to an emergency room with impaired consciousness. Of the ...
... University observed that anomalies in the part of the brain ... Recent studies have linked facial// recognition to a part of ... both the left and right sides of the brain. This ... seeing and also what they may be thinking or feeling ...
... for early outset glaucoma appears to slow the advancement of ... form of glaucoma appears to impact the progression of vision ... to detect it only in a detailed eye exam. In ... glaucoma in one eye. Around half of the group was ...
... to a new study it is observed that reducing blood ... half. It is already known that hypertension (high blood pressure) ... a study carried out by doctors in Dallas, the effect ... ,A group of patients with systolic hypertension - ...
Cached Medicine News:
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
... is a method for isolating antibodies, ... cells using affinity binding, while retaining ... on the particles to separate biotinylated ... the MagnaBind™ Beads from the suspension, ...
... m Dynabeads with covalently bound ... any biotinylated target. The Dynabeads® ... area, high capacity, magnetic pull ... during incubation. The MyOne™ products ...
Medicine Products: